ABSTRACT
Childhood and adolescent cancer survivors are disproportionately more likely to develop cardiovascular diseases from the late effects of cardiotoxic therapies (e.g., anthracycline-based chemotherapy and chest-directed radiotherapy). Currently, dexrazoxane is the only approved drug for preventing cancer treatment-related cardiac damage. While animal models highlight the beneficial effects of exercise cancer treatment-related cardiac dysfunction, few clinical studies have been conducted. Thus, the objective of this scoping review was to explore the designs and impact of exercise-based interventions for managing cancer treatment-related cardiac dysfunction in childhood and adolescent cancer survivors. Reviewers used Joanna Briggs Institute's methodology to identify relevant literature. Then, 4616 studies were screened, and three reviewers extracted relevant data from six reports. Reviewers found that exercise interventions to prevent cancer treatment-related cardiac dysfunction in childhood and adolescent cancer survivors vary regarding frequency, intensity, time, and type of exercise intervention. Further, the review suggests that exercise promotes positive effects on managing cancer treatment-related cardiac dysfunction across numerous indices of heart health. However, the few clinical studies employing exercise interventions for childhood and adolescent cancer survivors highlight the necessity for more research in this area.
Subject(s)
Cancer Survivors , Dexrazoxane , Heart Diseases , Neoplasms , Anthracyclines/adverse effects , Cardiotoxicity/etiology , Dexrazoxane/therapeutic use , Heart Diseases/chemically induced , Heart Diseases/drug therapy , Humans , Neoplasms/drug therapy , SurvivorsABSTRACT
Several factors unique to Fanconi anemia (FA) limit the success of allogeneic hematopoietic stem cell transplantation (HSCT) in this population. In this report, we describe a multi-center pilot study of five consecutive FA patients with high-risk features for transplant prepared with fludarabine, without radiation. Four patients engrafted quickly, experienced minimal toxicity and are well at 43-65 months post-transplant. One patient had a C-mismatched unrelated donor transplant and had unsustained engraftment. This fludarabine based regimen without radiation was safe and effective for four high-risk patients, suggesting that eliminating radiation should be further studied as an approach to HSCT in children with FA.
Subject(s)
Fanconi Anemia/surgery , Hematopoietic Stem Cell Transplantation , Transplantation Conditioning/methods , Vidarabine/analogs & derivatives , Adolescent , Child , Child, Preschool , Female , Follow-Up Studies , Graft Survival/drug effects , Humans , Male , Pilot Projects , Radiation , Risk Factors , Transplantation, Homologous , Treatment Outcome , Vidarabine/pharmacologyABSTRACT
Hurler syndrome is a lysosomal storage disease resulting in fatal cardiac or neurologic sequelae unless alpha-iduronidase production is reconstituted with hematopoietic stem cell transplantation. We report on a 4-year, 6-month-old boy with mixed donor chimerism and low enzyme levels but a normal neurodevelopmental trajectory.
Subject(s)
Bone Marrow Transplantation , Developmental Disabilities/prevention & control , Iduronidase/blood , Mucopolysaccharidosis I/therapy , Transplantation Chimera , Humans , Infant , Male , Treatment OutcomeABSTRACT
Adenovirus causes disseminated disease following bone marrow transplantation (BMT). We report a child who underwent T-cell-depleted BMT. Adenovirus subgenus F serotype 41 was detected antemortem by PCR in cerebrospinal fluid and postmortem in other tissues. Serotypes 40 and 41, associated with gastrointestinal disease, have not previously been implicated in disseminated disease.
